RxDoctor Payments Data

Stanley Michalski, MD

Rheumatology · Williamsville, NYNPI 1386649721

Payments from drug & device makers

$10,034in general payments, 2019–2025

Across 590 payments — averaging $17.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Pfizer$1K
  • AbbVie$1K
  • Lilly USA, LLC$855
  • GSK$748
  • Abbott$656
  • plus $4K from 42 others

What the payments were for

  • Food & beverage$9,88899%
  • Education$1461%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,034 in reported general payments places this provider in the 65th percentile of 541 rheumatology providers in New York.

See all rheumatology providers in New York

Medicare billing

Part B allowed, 2024
$25,906
Medicare patients
102
Services billed
433

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept43$329,103
Orencia ClickjectAbatacept16$94,800
RemicadeInfliximab11$92,174
EnbrelEtanercept12$89,352
RinvoqUpadacitinib11$68,771
Xeljanz XrTofacitinib Citrate12$63,977
OxycontinOxycodone Hcl74$63,566
BenlystaBelimumab13$58,433
ProliaDenosumab33$57,613
OrenciaAbatacept/Maltose11$55,484
EliquisApixaban45$36,950
JardianceEmpagliflozin18$23,717
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$17,645
LyricaPregabalin20$17,138
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen486$12,364

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel, Prolia$1,244$146,96545 claims
Johnson & JohnsonRemicade$387$92,17411 claims
GSKBenlysta, Trelegy Ellipta$748$76,07835 claims
AbbVieRinvoq, Synthroid$1,007$71,97747 claims
E.r. Squibb & Sons, L.L.C.Orencia$421$55,48411 claims
PfizerEliquis, Lyrica$1,165$54,08865 claims
Boehringer IngelheimJardiance$419$23,71718 claims
MerckBelsomra$109$5,06912 claims
Astellas Pharma US IncMyrbetriq$20$4,46611 claims
Collegium Pharmaceutical, Inc.Xtampza Er$24$3,91711 claims
Lilly USA, LLCHumalog$855$2,34512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 541 rheumatology providers in New York.

Other rheumatology in Williamsville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →